Related Experiment Videos

Catheter-related thrombosis: biological and clinical evidence for risk with currently available anticoagulants

Gilles Montalescot1, Jeanine M Walenga

  • 1Institut de Cardiogie, Centre Hospitalier Universitarie Pitié-Salpetrèire, Paris, France. gilles.montalescot@psl.ap-hop-paris.fr

Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
|January 2, 2009
PubMed

Insights

Anticoagulants for percutaneous coronary intervention (PCI) must balance preventing events and complications. Newer factor Xa inhibitors may increase catheter thrombosis risk compared to heparin agents.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Percutaneous coronary intervention (PCI) requires anticoagulation to prevent thrombotic events.
  • Current anticoagulants include unfractionated heparin (UFH), enoxaparin, fondaparinux, and bivalirudin.
  • UFH and enoxaparin demonstrate favorable efficacy and safety in PCI with rare catheter thrombosis.

Purpose of the Study:

  • To evaluate the safety and efficacy of anticoagulants during PCI.
  • To compare periprocedural complication rates among different anticoagulant classes.
  • To investigate the risk of catheter thrombosis with novel anticoagulants.

Main Methods:

  • Review of clinical trial data and experimental systems.
  • Comparison of heparin-based agents with newer anticoagulants, including factor Xa inhibitors.
  • Analysis of polytherapeutic versus single-target anticoagulant mechanisms.

Main Results:

  • Heparin-based agents (UFH, enoxaparin) show good efficacy and low complication rates in PCI.
  • Some factor Xa inhibitors are linked to higher catheter thrombosis rates versus heparin.
  • Polytherapeutic agents may offer superior anticoagulation compared to single-target agents.

Conclusions:

  • Anticoagulant choice for PCI impacts both efficacy and periprocedural safety.
  • Further research is needed to clarify the drivers of catheter thrombosis with novel agents.
  • Future trials must report periprocedural complication rates for novel anticoagulation therapies in PCI.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...